home > ict > summer 2020 > preserving trial integrity during a pandemic
International Clinical Trials

Preserving Trial Integrity During a Pandemic

The pharmaceutical industry is being impacted by the COVID-19 pandemic in ways not seen before. From decreased recruitment rates due to enforced social distancing policies, to a complete halt in drug development programmes as companies project their budgets. Trials are not being run as usual, and the pandemic’s effect on ongoing clinical trials may threaten scientific accuracy and regulatory compliance. However, with the correct changes and statistical methodologies in place, a study’s integrity can be preserved.

Sample Size: Are We Good or Not?

The right sample size ensures a successful study while balancing costs and minimising the number of patients undergoing potentially invasive procedures. We might think of continuing as planned until normality is restored, however, the costs of running a study that doesn’t deliver results in the agreed timelines can be overwhelming for major pharma companies, and a killer for smaller biotech companies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Author

Karen Ooms is responsible for overseeing the strategic delivery business unit for Quanticate. This includes the supervision of the clinical data management, biostatistics, programming, medical writing, and pharmacovigilance departments. Karen is a Chartered Fellow of the Royal Statistical Society and has a background in biostatistics spanning over 25 years. Prior to joining Quanticate in 1999 (Statwood), Karen was a senior statistician at Unilever.
Print this page
Send to a friend
Privacy statement
News and Press Releases

SGD Pharma introduces Ensiemo, the new complete child-resistant packaging solution for CBD oils

SGD Pharma today announces the launch of its new full packaging solution dedicated to the cannabidiol (CBD) oil market. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed Ensiemo – a glass dropper and bottle offering that meets international regulatory standards.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement